About us
Our leadership team has experience in managing both small and large public and private companies through various stages of growth and financing strategies (venture capital, M&A transactions, IPOs, PIPEs).
They successfully sold the surface modification business of Interface Biologics to Evonik (ETR:EVK) in 2019 and founded Ripple Therapeutics in January of 2020.
Leadership Team
Board of directors
Medical advisory board
